MarginsXMarginsX
Home › Markets › Health Care › BRVE

Braveheart Bio Inc. (BRVE)

BRVE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$19.49
-0.66% on the day
Market cap
$1.8B
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerBRVE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2026
SEC CIK0002131524
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
29.0 months
$121.3M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$122.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"The Company has evaluated whether there are conditions and events considered in the aggregate that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed financial statements are issued."
10-Q 2026-11-10
Cash and burn$121.3M cash; operating cash flow -$12.6M a quarter.Report 2026-09-30
Shares outstanding89,870,352 (2026-11-06).Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-08-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $122.6M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$26.5M-$24.4M$121.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2026-06-30
Not filed-$15.0MNot filed$122.8MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2026-03-31
Not filed-$14.3MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2025-09-30
Not filed-$59.1M-$740K$67.5MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2025-06-30
Not filed-$381KNot filed$2KNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2025-03-31
Not filed-$99KNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
S-1/A
424B42026-08-06
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10

Source: SEC EDGAR submissions feed, 53 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.5%
1 month+1.5%
3 months-24.5%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-34.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
STOKStoke Therapeutics Inc.$26.63-0.19%$1.7B
AGIOAgios Pharmaceuticals Inc.$30.15-4.56%$1.8B
ZYMEZymeworks Inc.$26.45+0.80%$1.8B
ETONEton Pharmaceuticals Inc.$63.88-0.08%$1.8B
KLRAKailera Therapeutics Inc.$12.57-5.28%$1.6B
SRPTSarepta Therapeutics Inc. Common Stock (DE)$15.13-5.85%$1.6B
RAREUltragenyx Pharmaceutical Inc.$15.90-1.12%$1.6B
ZBIOZenas BioPharma Inc.$27.93-0.29%$1.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier